Log in

Esperion Therapeutics Price Target, Predictions & Analyst Ratings

+0.46 (+1.44 %)
(As of 10/23/2020 12:00 AM ET)
Today's Range
Now: $32.31
50-Day Range
MA: $36.08
52-Week Range
Now: $32.31
Volume345,900 shs
Average Volume702,514 shs
Market Capitalization$899.03 million
P/E RatioN/A
Dividend YieldN/A

Analyst Ratings

Esperion Therapeutics (NASDAQ:ESPR) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Esperion Therapeutics in the last 12 months. Their average twelve-month price target is $80.50, predicting that the stock has a possible upside of 149.15%. The high price target for ESPR is $191.00 and the low price target for ESPR is $35.00. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
ESPR Consensus Rating: BuyBuyBuyBuy
ESPR Consensus Rating Score: 2.582.672.692.67
ESPR Analyst Ratings: 1 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
ESPR Consensus Price Target: $80.50$81.75$81.46$85.83
ESPR Price Target Upside: 149.15% upside74.32% upside69.69% upside73.35% upside

Esperion Therapeutics (NASDAQ:ESPR) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Esperion Therapeutics (NASDAQ:ESPR) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/15/2020Bank of AmericaLower Price TargetBuy$55.00 ➝ $52.00Low
9/29/2020JPMorgan Chase & Co.Initiated CoverageSell$35.00Low
8/11/2020Needham & Company LLCReiterated RatingBuy$158.00High
8/10/2020Stifel NicolausReiterated RatingBuy$75.00High
8/10/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$83.00 ➝ $45.00High
6/23/2020Northland SecuritiesInitiated CoverageHold$42.00High
5/7/2020Jefferies Financial GroupLower Price TargetBuy$85.00 ➝ $70.00High
5/7/2020CitigroupBoost Price TargetBuy$46.00 ➝ $56.00High
2/27/2020CowenReiterated RatingBuy$87.00Medium
2/24/2020JMP SecuritiesReiterated RatingOutperform$191.00Medium
2/19/2020BTIG ResearchReiterated RatingBuy$90.00Medium
1/31/2020Chardan CapitalReiterated RatingHold$65.00High
9/16/2019Goldman Sachs GroupUpgradeSell ➝ Neutral$55.00 ➝ $45.00Medium
5/16/2018UBS GroupSet Price TargetBuy$90.00 ➝ $75.00Low
5/3/2018Deutsche Bank AktiengesellschaftLower Price TargetBuy ➝ Buy$100.00 ➝ $75.00High
(Data available from 10/26/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.